Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Improves Metabolism: Imagine your body as a car
Research-Use-Only Laboratory Material Lyophilized powder supplied in standard laboratory vials
Blood sugar fluctuations, particularly in users who inject while fasting
Used to treat rare problems like idiopathic angioneurotic edema
La dose habituelle pour les adultes est de 0,25 2 ml